Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-9563
- Development stage
- Phase 2
- Lead developer
- Suncadia Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
HRS-9563 is a small interfering RNA (siRNA) pharmaceutical agent under clinical development for the treatment of mild hypertension. It functions as an **angiotensinogen (AGT) inhibitor**, thereby reducing the expression of the AGT protein, a key component of the renin-angiotensin system involved in blood pressure regulation. By inhibiting AGT expression, HRS-9563 aims to lower blood pressure through gene-silencing mechanisms. Developed originally by Fujian Suncadia Pharmaceuticals and later advanced by Fujian Shengdi Pharmaceutical (a subsidiary of Hengrui Pharmaceutical), HRS-9563 is designed for subcutaneous administration and is currently in Phase 1 clinical trials in China for hypertension. It represents a novel approach among antihypertensive therapies, leveraging siRNA technology to target cardiovascular diseases.[1][2][3][5][7]
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on HRS-9563.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-9563.